Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Zacks Research lowered its Q3 2026 earnings estimate for Vertex Pharmaceuticals from $4.15 to $4.13 per share. Other analysts ...

The stock's fall snapped a four-day winning streak.

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

AI names and growth stocks have stumbled in early 2025. 2024’s big stock market winners are among the worst performers in recent weeks. AI stocks have plunged double digits amid a wave of challenging ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...

Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Longeveron in a note ...